176 related articles for article (PubMed ID: 33524556)
1. Molecular characterization of clinical isolates of Enterobacterales with elevated MIC values for aztreonam-avibactam from the INFORM global surveillance study, 2012-2017.
Estabrook M; Kazmierczak KM; Wise M; Arhin FF; Stone GG; Sahm DF
J Glob Antimicrob Resist; 2021 Mar; 24():316-320. PubMed ID: 33524556
[TBL] [Abstract][Full Text] [Related]
2. Activity of aztreonam/avibactam against metallo-β-lactamase-producing Enterobacterales from the UK: Impact of penicillin-binding protein-3 inserts and CMY-42 β-lactamase in Escherichia coli.
Livermore DM; Mushtaq S; Vickers A; Woodford N
Int J Antimicrob Agents; 2023 May; 61(5):106776. PubMed ID: 36893810
[TBL] [Abstract][Full Text] [Related]
3. Investigation of mechanisms responsible for decreased susceptibility of aztreonam/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019.
Mendes RE; Doyle TB; Streit JM; Arhin FF; Sader HS; Castanheira M
J Antimicrob Chemother; 2021 Oct; 76(11):2833-2838. PubMed ID: 34436603
[TBL] [Abstract][Full Text] [Related]
4. Characterization of Escherichia coli NDM isolates with decreased susceptibility to aztreonam/avibactam: role of a novel insertion in PBP3.
Alm RA; Johnstone MR; Lahiri SD
J Antimicrob Chemother; 2015 May; 70(5):1420-8. PubMed ID: 25634992
[TBL] [Abstract][Full Text] [Related]
5. Activity of aztreonam/avibactam and ceftazidime/avibactam against Enterobacterales with carbapenemase-independent carbapenem resistance.
Mushtaq S; Vickers A; Woodford N; Livermore DM
Int J Antimicrob Agents; 2024 Mar; 63(3):107081. PubMed ID: 38176458
[TBL] [Abstract][Full Text] [Related]
6. Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-β-lactamase producers.
Crandon JL; Nicolau DP
Antimicrob Agents Chemother; 2013 Jul; 57(7):3299-306. PubMed ID: 23650162
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of cefepime/zidebactam and cefepime/taniborbactam against aztreonam/avibactam-resistant NDM-like-producing Escherichia coli clinical isolates.
Le Terrier C; Nordmann P; Sadek M; Poirel L
J Antimicrob Chemother; 2023 May; 78(5):1191-1194. PubMed ID: 36921067
[TBL] [Abstract][Full Text] [Related]
8. Activity of aztreonam in combination with novel β-lactamase inhibitors against metallo-β-lactamase-producing Enterobacterales from Spain.
Vázquez-Ucha JC; Alonso-Garcia I; Guijarro-Sánchez P; Lasarte-Monterrubio C; Álvarez-Fraga L; Cendón-Esteve A; Outeda M; Maceiras R; Peña-Escolano A; Martínez-Guitián M; Arca-Suárez J; Bou G; Beceiro A;
Int J Antimicrob Agents; 2023 Apr; 61(4):106738. PubMed ID: 36736925
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of aztreonam-avibactam against Enterobacterales isolates collected in Latin America, Africa/Middle East, Asia, and Eurasia for the ATLAS Global Surveillance Program in 2019-2021.
Wise MG; Karlowsky JA; Mohamed N; Kamat S; Sahm DF
Eur J Clin Microbiol Infect Dis; 2023 Sep; 42(9):1135-1143. PubMed ID: 37526796
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of aztreonam-avibactam against metallo-β-lactamase-producing Enterobacteriaceae-A multicenter study in China.
Zhang B; Zhu Z; Jia W; Qu F; Huang B; Shan B; Yu H; Tang Y; Chen L; Du H
Int J Infect Dis; 2020 Aug; 97():11-18. PubMed ID: 32473388
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Dilution Susceptibility Testing Methods for Aztreonam in Combination with Avibactam against Enterobacterales.
Kelley CJ; Kennedy-Mendez A; Walser ON; Thwaites MT; Arhin FF; Pillar CM; Hufnagel DA
Microbiol Spectr; 2022 Dec; 10(6):e0360122. PubMed ID: 36342288
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of aztreonam in combination with newly developed β-lactamase inhibitors against MDR Enterobacterales and Pseudomonas aeruginosa producing metallo-β-lactamases.
Le Terrier C; Nordmann P; Poirel L
J Antimicrob Chemother; 2022 Dec; 78(1):101-107. PubMed ID: 36308322
[TBL] [Abstract][Full Text] [Related]
13. Genetic Features Leading to Reduced Susceptibility to Aztreonam-Avibactam among Metallo-β-Lactamase-Producing Escherichia coli Isolates.
Sadek M; Juhas M; Poirel L; Nordmann P
Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32988825
[TBL] [Abstract][Full Text] [Related]
14. Incidence of ESBLs and carbapenemases among Enterobacterales and carbapenemases in Pseudomonas aeruginosa isolates collected globally: results from ATLAS 2017-2019.
Gales AC; Stone G; Sahm DF; Wise MG; Utt E
J Antimicrob Chemother; 2023 Jul; 78(7):1606-1615. PubMed ID: 37161662
[TBL] [Abstract][Full Text] [Related]
15. Molecular Characterization of Carbapenem-Nonsusceptible Enterobacterial Isolates Collected during a Prospective Interregional Survey in France and Susceptibility to the Novel Ceftazidime-Avibactam and Aztreonam-Avibactam Combinations.
Dupont H; Gaillot O; Goetgheluck AS; Plassart C; Emond JP; Lecuru M; Gaillard N; Derdouri S; Lemaire B; Girard de Courtilles M; Cattoir V; Mammeri H
Antimicrob Agents Chemother; 2016 Jan; 60(1):215-21. PubMed ID: 26482307
[TBL] [Abstract][Full Text] [Related]
16.
Kazmierczak KM; Bradford PA; Stone GG; de Jonge BLM; Sahm DF
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249690
[No Abstract] [Full Text] [Related]
17. Aztreonam-Avibactam Susceptibility Testing Program for Metallo-Beta-Lactamase-Producing
Bhatnagar A; Boyd S; Sabour S; Bodnar J; Nazarian E; Peinovich N; Wagner C; Craft B; Snippes Vagnone P; Simpson J; Stone VN; Therrien M; Bateman A; Lower D; Huang JY; Gumbis S; Lonsway D; Lutgring JD; Karlsson M; Brown AC
Antimicrob Agents Chemother; 2021 Jul; 65(8):e0048621. PubMed ID: 34060895
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Contemporary (2016) Clinical Enterobacteriaceae Isolates.
Sader HS; Mendes RE; Pfaller MA; Shortridge D; Flamm RK; Castanheira M
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061754
[TBL] [Abstract][Full Text] [Related]
19. Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and β-lactamases with ceftazidime hydrolytic activity lead to elevated MIC values.
Castanheira M; Doyle TB; Hubler C; Sader HS; Mendes RE
Int J Antimicrob Agents; 2020 Jul; 56(1):106011. PubMed ID: 32417206
[TBL] [Abstract][Full Text] [Related]
20. Aztreonam-avibactam may not replace ceftazidime/avibactam: the case of KPC-21 carbapenemase and penicillin-binding protein 3 with four extra amino acids.
Ma K; Feng Y; Zong Z
Int J Antimicrob Agents; 2022 Sep; 60(3):106642. PubMed ID: 35872296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
